Three people with a muscle-destroying disease destined to worsen got a little stronger when an implanted device zapped their ...

In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease.

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

How a tiny spinal implant could help those with muscle-wasting disease - Three people with a muscle-destroying disease got ...

Boosting communication between the spinal nerves and the muscles using the spinal cord stimulation reverses spinal muscle ...

Novartis is on the final straight to approval of its spinal muscular atrophy (SMA) gene therapy Zolgensma in the EU, after getting a recommendation for approval from the CHMP. The positive opinion ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an ...

Novartis' gene therapy portfolio includes spinal muscular atrophy treatment Zolgensma (onasemnogene abeparvovec) – used to treat upwards of 3,400 patients worldwide with third-quarter sales of $ ...

We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...

A case report described an infant with concurrent HDFN and SMA who was succesfully treated with an onasemnogene abeparvovec ...